<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04144257</url>
  </required_header>
  <id_info>
    <org_study_id>2019P002356</org_study_id>
    <nct_id>NCT04144257</nct_id>
  </id_info>
  <brief_title>Role of Microglial Activation and Norepinephrine Transporter Abnormalities in Pathogenesis of MS-related Fatigue</brief_title>
  <official_title>Role of Microglial Activation and Norepinephrine Transporter Abnormalities in Pathogenesis of MS-related Fatigue</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Brigham and Women's Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>U.S. Army Medical Research Acquisition Activity</agency>
      <agency_class>U.S. Fed</agency_class>
    </collaborator>
  </sponsors>
  <source>Brigham and Women's Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The overarching aim is to assess the role of microglial activation and norepinephrine&#xD;
      transporter binding in pathogenesis of MS-related fatigue, using novel Positron Emission&#xD;
      Tomography (PET) radiotracers, [F-18]PBR06 and [C-11]MRB.&#xD;
&#xD;
      Specific Aims:&#xD;
&#xD;
      Specific Aim 1: To determine the relationship of cerebral microglial activation, as assessed&#xD;
      by [F-18]PBR06 PET, with MS-related fatigue.&#xD;
&#xD;
      Specific Aim 2: To determine the relationship of norepinephrine transporter (NET) binding, as&#xD;
      assessed by [C-11]MRB PET, with MS-related fatigue.&#xD;
&#xD;
      Specific Aim 3: To determine the relationship of microglial activation and NET binding, with&#xD;
      grey matter pathology (lesion load and brain atrophy) assessed using 7T MRI, and evaluate&#xD;
      their independent contribution in development of MS-related fatigue.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Design: This is a single center, cross-sectional study of patients with multiple sclerosis,&#xD;
      who will each, undergo both, [C-11]MRB-PET (norepinephrine transporter binding) and&#xD;
      [F-18]PBR06-PET (microglial activation), in addition to 7 Tesla brain MRIs. Patients will&#xD;
      also undergo cross-sectional estimations of blood markers.&#xD;
&#xD;
      Genotype Testing:&#xD;
&#xD;
      Blood sample drawn on the initial screening visit will be used to obtain genomic DNA for&#xD;
      genotyping for polymorphism within the TSPO gene on chromosome 22q13.2, using a Taqman assay.&#xD;
      High affinity and medium affinity binders will be included while the low affinity binders&#xD;
      will be excluded from the study.&#xD;
&#xD;
      PET Scanning:&#xD;
&#xD;
      During the PET scan visits, all women subjects of child bearing age will undergo a stat&#xD;
      quantitative serum hCG pregnancy test and only women with a negative test will undergo the&#xD;
      radiopharmaceutical injection. The radiotracers will be produced using standardized&#xD;
      procedures. At the time of imaging, the subjects will be positioned in the gantry of a&#xD;
      high-resolution PET/CT camera. Head alignment will be made, relative to the canthomeatal&#xD;
      line, using projected laser lines whose positions are known with respect to the slice&#xD;
      positions of the scanner. A head support apparatus will be used to minimize head&#xD;
      motion.Dynamic data over 120 minutes for PET quantification will be acquired, according to&#xD;
      previously described methods for both tracers.&#xD;
&#xD;
      MRI Scanning:&#xD;
&#xD;
      High resolution MRI scanning will be performed using the 7T Siemens MAGNETOM Terra MRI unit&#xD;
      at Brigham &amp; Women's Hospital (BWH).&#xD;
&#xD;
      Serum assays:&#xD;
&#xD;
      Serum measurements for inflammatory markers and relevant neurochemicals will be performed&#xD;
      according to established procedures.&#xD;
&#xD;
      Clinical Data&#xD;
&#xD;
      The following non-imaging, clinical data will be obtained:&#xD;
&#xD;
      Modified fatigue Impact Scale (MFIS) Fatigue Severity Status Scale (FSSS) Expanded Disability&#xD;
      Status Scale (EDSS) Timed 25-feet walk (T25W) MS Functional Composite (MSFC) Symbol digit&#xD;
      modalities test (SDMT) MSQOL-54 scale (QOL) Pittsburgh Sleep Quality Index (PSQI) Beck's&#xD;
      Depression Inventory (BDI) Center for Epidemiological Studies-Depression Scale (CES-D)&#xD;
      Hospital Anxiety and Depression Scale (HADS)&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 12, 2020</start_date>
  <completion_date type="Anticipated">September 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">September 30, 2021</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Standardized Uptake Value (SUV)/Standardized Uptake Value Ratio (SUVR)</measure>
    <time_frame>Baseline</time_frame>
    <description>PET outcome measure</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Modified Fatigue Impact Scale (MFIS)</measure>
    <time_frame>Baseline</time_frame>
    <description>Clinical outcome measure; Physical subscale range: 0-36; Cognitive subscale range: 0-40; Psychosocial subscale range: 0-8; Total MFIS Score scale range (Subscales Summed): 0-84; Higher values represent worse outcomes.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Binding Potential (BPnd)</measure>
    <time_frame>Baseline</time_frame>
    <description>PET outcome measure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MRI grey matter lesional load/brain atrophy</measure>
    <time_frame>Baseline</time_frame>
    <description>MRI outcome measure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tissue Volume of distribution (Vt)/Distribution Volume Ratios (DVR)</measure>
    <time_frame>Baseline</time_frame>
    <description>PET outcome measure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MRI global/regional volumetrics</measure>
    <time_frame>Baseline</time_frame>
    <description>MRI outcome measure</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">12</enrollment>
  <condition>Multiple Sclerosis</condition>
  <arm_group>
    <arm_group_label>Subjects diagnosed with Multiple Sclerosis (MS)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>We plan to enroll 12 subjects with multiple sclerosis (6 with relapsing multiple sclerosis and 6 with secondary progressive multiple sclerosis).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>[F-18]PBR06</intervention_name>
    <description>PET radiopharmaceutical. Subjects will undergo [F-18]PBR06-PET (microglial activation).</description>
    <arm_group_label>Subjects diagnosed with Multiple Sclerosis (MS)</arm_group_label>
    <other_name>[18F]PBR06</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>[C-11]Methylreboxetine</intervention_name>
    <description>PET radiopharmaceutical. Subjects will undergo [C-11]MRB-PET (norepinephrine transporter binding).</description>
    <arm_group_label>Subjects diagnosed with Multiple Sclerosis (MS)</arm_group_label>
    <other_name>[C-11]MRB</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Subjects meeting the definition for RRMS or SPMS by International Panel (2017&#xD;
             McDonald) Criteria.&#xD;
&#xD;
          -  We will recruit patients with RRMS, recently diagnosed in the last 2 years. There will&#xD;
             be no disease modifying therapy restrictions for RRMS or SPMS patients.&#xD;
&#xD;
          -  Male and female subjects age 18 to 60 years.&#xD;
&#xD;
          -  Patients able to withhold medication that may interfere with C-11[MRB] radiotracer&#xD;
             uptake for 24 hours before the scan.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Relapse/Corticosteroid treatment in the past 4 weeks to avoid transient effects on&#xD;
             imaging&#xD;
&#xD;
          -  Individuals with a known alternate neurologic disorder, previous head injury, or&#xD;
             substance abuse.&#xD;
&#xD;
          -  Individuals with bipolar disease and schizophrenia&#xD;
&#xD;
          -  Concurrent medical conditions that contraindicate study procedures.&#xD;
&#xD;
          -  Women who are pregnant or nursing. Also, any woman who is seeking to become pregnant&#xD;
             or suspects she is pregnant will be excluded from enrollment.&#xD;
&#xD;
          -  Claustrophobia&#xD;
&#xD;
          -  Non-MRI compatible implanted devices&#xD;
&#xD;
          -  Low affinity binders&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tarun Singhal, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Brigham and Women's Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Tarun Singhal, MD</last_name>
    <phone>617-264-3043</phone>
    <email>tsinghal@bwh.harvard.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Partners MS Center, 60 Fenwood Road</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Steven Vaquerano</last_name>
      <phone>617-264-3044</phone>
      <email>svaquerano2@bwh.harvard.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>October 28, 2019</study_first_submitted>
  <study_first_submitted_qc>October 28, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">October 30, 2019</study_first_posted>
  <last_update_submitted>July 26, 2021</last_update_submitted>
  <last_update_submitted_qc>July 26, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 28, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Brigham and Women's Hospital</investigator_affiliation>
    <investigator_full_name>TARUN SINGHAL</investigator_full_name>
    <investigator_title>Assistant Professor of Neurology</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Sclerosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

